Fluorobenzenes
Medchemexpress LLC PDGFRα kinase inhibitor 1 | 2209053-93-8 | 98.5% | 586.69 | 50 MG
PDGFRα kinase inhibitor 1 is a highly selective type II PDGFRα kinase inhibitor with IC50s of 132 nM for PDGFRα and 6115 nM for PDGFRβ. It is for research use only and not sold to patients.
- Highly selective type II PDGFRα kinase inhibitor
- Exhibits weak inhibition to DDR1 kinase (IC50: 2462±126 nM)
Medchemexpress LLC HY-10322 5mg Medchemexpress, Falnidamol CAS:196612-93-8 Purity:>98%
Medchemexpress, HY-10322 5mg Falnidamol CAS:196612-93-8 Falnidamol (BIBX 1382) is an orally active, selective EGFR tyrosine kinase inhibitor with an IC50 of 3 nM. Falnidamol displays > 1000-fold lower potency against ErbB2 (IC50=3.4 μM) and a range of other related tyrosine kinases (IC50>10 μM). Falnidamol is a pyrimido-pyrimidine compound and has anti-cancer activity. Purity:>98% Medchemexpress has over 10000 novel life-science reagents, reference compounds, APIs and natural compounds for laboratory and scientific use. Other quantity can also be offered.
eMolecules Medchem Express / Falnidamol / 5mg / 446258018 / HY-10322 / / 196612-93-8 / MFCD09838900 / 387.850 / C18H19ClFN7
Medchem Express / Falnidamol / 5mg / 446258018 / HY-10322 / / 196612-93-8 / MFCD09838900 / 387.850 / C18H19ClFN7
eMolecules Medchem Express / NVP-BSK805 / 5mg / 415687310 / HY-14722 / / 1092499-93-8 / MFCD22419018 / 490.559 / C27H28F2N6O
Medchem Express / NVP-BSK805 / 5mg / 415687310 / HY-14722 / / 1092499-93-8 / MFCD22419018 / 490.559 / C27H28F2N6O
Selleck Chemical LLC GK921
GK921 is a transglutaminase 2 (TGase 2) inhibitor with an IC50 of 8 93 M under a modified assay condition
Apexbio Technology LLC Altiratinib 1345847-93-9 10mg
Altiratinib (DCC-2701 CAS 1345847-93-9) is a multi-targeted small molecule inhibitor designed to block the activity of the receptor tyrosine kinases c-MET TIE-2 and VEGFR It demonstrates potent inhibitory activity with reported IC50 values of 2 7 nM for c-MET 8 0 nM for TIE-2 and 9 2 nM for VEGFR In cell-based assays Altiratinib suppresses phosphorylation of MET in MET-overexpressing EBC-1 and MKN-45 cell lines and inhibits TIE2 and VEGFR2 activation in endothelial models In preclinical xenograft studies Altiratinib reduces MET phosphorylation and tumor burden This compound is utilized to investigate pathways involved in tumor growth angiogenesis and microenvironment-mediated drug resistance